Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 14/20 | 0.68 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062637 | 0.92 | KCNN4 (0.63) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL5052363 | 0.88 | MAPT (0.56) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL5055356 | 0.83 | KCNN4 (0.67) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL5056428 | 0.81 | MAPT (0.46) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL2337394 | 0.81 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| Senicapoc SCHEMBL1443805 | 0.81 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL28875440 | 0.81 | KCNN4 (0.72) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL28151671 | 0.78 | KCNN4 (0.68) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL5060670 | 0.77 | KIF11 (0.50) | MAPTKMT2AKIF11NPC1RAB9A | |
| SCHEMBL12811863 | 0.75 | KCNN4 (0.86) | KCNN4KCNE1KCNQ1KIF11NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119456-A1 | Substituted Thiazoleacetic Acid as Crth2 Ligands | 7TM PHARMA A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| EP-1758874-A1 | SUBSTITUTED THIAZOLEACETIC ACIDS AS CRTH2 LIGANDS | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005116001-A1 | SUBSTITUTED THIAZOLEACETIC AS CRTH2 LIGANDS | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119456-A1 | Substituted Thiazoleacetic Acid as Crth2 Ligands | HRH1, HRH2, HRH3 | KCNN4 3602/4885KCNE1 2529/4885KCNQ1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.